Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 2/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osajin SCHEMBL22093541 | 0.97 | PTPN1 (0.95) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| Osajin SCHEMBL27659828 | 0.96 | PTPN1 (0.93) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL18906967 | 0.94 | PTPN1 (0.88) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| Warangalone SCHEMBL571534 | 0.93 | PTPN1 (0.86) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL11911697 | 0.91 | CYP3A4 (0.84) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| Pomiferin SCHEMBL8059171 | 0.90 | CYP3A4 (1.00) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL22108474 | 0.90 | PTPN1 (0.81) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL24305393 | 0.89 | CYP3A4 (0.81) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL24305356 | 0.89 | CYP3A4 (0.85) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL18906963 | 0.89 | CYP3A4 (0.87) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1899 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082672-A1 | METAL (HYDR) OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CNPHARM CO., LTD. (KR) | 2025-03-13 | — | — | US | claimed |
| EP-4520339-A2 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Webiotree Co., Ltd. (KR) | 2025-03-12 | — | — | EP | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023182736-A1 | MULTI-LAYERED TABLET COMPOSITE FORMULATION AND PREPARATION METHOD THEREFOR | 주식회사 위바이오트리 | 2023-09-28 | — | — | WO | claimed |
| US-20230233483-A1 | COMPOUND AND METHOD FOR THE TREATMENT OF CORONAVIRUSES | APTEEUS (FR) | 2023-07-27 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| US-20230040651-A1 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WEBIOTREE CO., LTD. (KR) | 2023-02-09 | — | — | US | claimed |
| EP-4091603-A1 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Webiotree Co., Ltd. (KR) | 2022-11-23 | — | — | EP | claimed |
| US-20220323356-A1 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CNPHARM CO., LTD. (KR) | 2022-10-13 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-1395573-A | Extraction of flavonoids | BIOREX HEALTH LTD (AU) | 2003-02-05 | — | — | CN | claimed |
| CN-1376050-A | Skin care composition | UNILEVER PLC (NL) | 2002-10-23 | — | — | CN | claimed |
| CN-1365620-A | Functional food for preventing damage of mobile telephone radiation | MI MANTIAN (CN) | 2002-08-28 | — | — | CN | claimed |
| CN-1352935-A | Cosmetics composition containing aminophenol derivatives and isoflavone like substance | OREAL (FR) | 2002-06-12 | — | — | CN | claimed |
| CN-1347459-A | Novel substance originating in basidiomycete culture, process for producing same and use thereof | AMINO UP CHEMICAL CO LTD (JP) | 2002-05-01 | — | — | CN | claimed |
| CN-1333681-A | Method for reducing blood cholesterol and/or blood triglycerides | EASTMAN CHEM CO (US) | 2002-01-30 | — | — | CN | claimed |
| EP-1151295-A1 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | Cytovia, Inc. (US) | 2001-11-07 | — | — | EP | claimed |
| CN-1312712-A | Therapeutic composition based on flavonoids for use in treatment of tumours with cytotoxic agents | L LAB (FR) | 2001-09-12 | — | — | CN | claimed |
| CN-1310610-A | Pharmaceutical composition for preventing and treating radiation mucositis and chemical mucositis | LAFON LABOR (FR) | 2001-08-29 | — | — | CN | claimed |
| WO-2000045165-A1 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | CYTOVIA, INC. (US) | 2000-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040651-A1 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HAAO, HAO2, HAO1 | PTPN1 566/4885CYP3A4 99/4885MAPT 406/4885 |
| US-20250082672-A1 | METAL (HYDR) OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HAAO, HAO2, HAO1 | PTPN1 566/4885CYP3A4 99/4885MAPT 406/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | PTPN1 4752/4885CYP3A4 3571/4885MAPT 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.